trihexyphenidyl has been researched along with Disease Models, Animal in 18 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trihexyphenidyl (THP), a non-selective muscarinic receptor (mAChR) antagonist, is commonly used for the treatment of dystonia associated with TOR1A, otherwise known as DYT1 dystonia." | 4.12 | Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia. ( Donsante, Y; Downs, AM; Hess, EJ; Jinnah, HA, 2022) |
| "Administration of imipramine plus serotonin (5-HT) to rats has been proposed as an animal model of Duchenne muscular dystrophy." | 3.65 | Skeletal muscle necrosis following membrane-active drugs plus serotonin. ( Meltzer, HY, 1976) |
| "Dystonia is a disabling neurological syndrome characterized by abnormal movements and postures that result from intermittent or sustained involuntary muscle contractions; mutations of DYT1/TOR1A are the most common cause of childhood-onset, generalized, inherited dystonia." | 1.51 | A Novel Transgenic Mouse Model to Investigate the Cell-Autonomous Effects of torsinA(ΔE) Expression in Striatal Output Neurons. ( Beauvais, G; Ehrlich, ME; Gonzalez-Alegre, P; Koch, RJ; Martin, J; Patel, JC; Rice, ME; Walker, RH, 2019) |
| "Trihexyphenidyl was less effective at enhancing dopamine release in Dyt1 mice relative to controls ex vivo (mean increase WT: 65% vs Dyt1: 35%)." | 1.51 | Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. ( Donsante, C; Downs, AM; Fan, X; Hess, EJ; Jinnah, HA, 2019) |
| "DYT1 early-onset generalized torsion dystonia is an inherited movement disorder associated with mutations in DYT1 that codes for torsinA protein." | 1.38 | An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 ΔGAG knock-in mice. ( Cheetham, CC; Dang, MT; Li, Y; Lovinger, DM; Lu, J; Vo, V; Yokoi, F, 2012) |
| "Trihexyphenidyl (THP) is a drug commonly used to reduce parkinsonian symptoms." | 1.32 | Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats. ( Alvarez-Cervera, F; Arankowsky-Sandoval, G; Góngora-Alfaro, JL; Moo-Puc, RE; Villanueva-Toledo, J, 2004) |
| " After chronic haloperidol dosing (vehicle, 0." | 1.30 | Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. ( Fowler, SC; Wang, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (33.33) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Downs, AM | 2 |
| Donsante, Y | 1 |
| Jinnah, HA | 2 |
| Hess, EJ | 2 |
| Gonzalez-Alegre, P | 1 |
| Beauvais, G | 1 |
| Martin, J | 1 |
| Koch, RJ | 1 |
| Walker, RH | 1 |
| Patel, JC | 1 |
| Rice, ME | 1 |
| Ehrlich, ME | 1 |
| Kaur, H | 1 |
| Kaur, R | 1 |
| Jaggi, AS | 1 |
| Bali, A | 1 |
| Fan, X | 1 |
| Donsante, C | 1 |
| Fish, EW | 1 |
| Krouse, MC | 1 |
| Stringfield, SJ | 1 |
| Diberto, JF | 1 |
| Robinson, JE | 1 |
| Malanga, CJ | 1 |
| Yoshiyama, Y | 1 |
| Kojima, A | 1 |
| Itoh, K | 1 |
| Uchiyama, T | 1 |
| Arai, K | 1 |
| Dang, MT | 1 |
| Yokoi, F | 1 |
| Cheetham, CC | 1 |
| Lu, J | 1 |
| Vo, V | 1 |
| Lovinger, DM | 1 |
| Li, Y | 1 |
| Moo-Puc, RE | 1 |
| Villanueva-Toledo, J | 1 |
| Arankowsky-Sandoval, G | 1 |
| Alvarez-Cervera, F | 1 |
| Góngora-Alfaro, JL | 1 |
| Ohno, Y | 1 |
| Shimizu, S | 1 |
| Imaki, J | 1 |
| Ishihara, S | 1 |
| Sofue, N | 1 |
| Sasa, M | 1 |
| Kawai, Y | 1 |
| Kehr, W | 1 |
| Fowler, SC | 1 |
| Wang, G | 1 |
| Meltzer, HY | 1 |
| Borison, RL | 1 |
| Havdala, HS | 1 |
| Diamond, BI | 1 |
| Matthews, RT | 1 |
| Chiou, CY | 1 |
| Kryzhanovskiĭ, GN | 2 |
| Atadzhanov, MA | 1 |
| Voronina, TA | 1 |
| Nerobkova, LN | 1 |
| Makul'kin, RF | 1 |
| Shandra, AA | 1 |
| Godlevskiĭ, LS | 1 |
| Rozhkov, VS | 1 |
18 other studies available for trihexyphenidyl and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia.
Topics: Animals; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dys | 2022 |
A Novel Transgenic Mouse Model to Investigate the Cell-Autonomous Effects of torsinA(ΔE) Expression in Striatal Output Neurons.
Topics: Animals; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dystonia; Electric Stimulation; | 2019 |
Beneficial role of central anticholinergic agent in preventing the development of symptoms in mouse model of post-traumatic stress disorder.
Topics: Animals; Behavior, Animal; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; | 2020 |
Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dystonia Musculorum Deformans; Gene Knoc | 2019 |
Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Blotting, Western; Cocaine; Disease M | 2013 |
Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model.
Topics: Animals; Benzilates; Cholinergic Antagonists; Disease Models, Animal; Hippocampus; Inflammation; Mic | 2012 |
An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 ΔGAG knock-in mice.
Topics: Animals; Calcium Channel Agonists; Corpus Striatum; Disease Models, Animal; Dystonia Musculorum Defo | 2012 |
Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Diseas | 2004 |
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2008 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 1998 |
Skeletal muscle necrosis following membrane-active drugs plus serotonin.
Topics: Animals; Antidepressive Agents, Tricyclic; Disease Models, Animal; Drug Synergism; Histamine H1 Anta | 1976 |
A new animal model for schizophrenia: cholinergic and serotonergic modulation.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Dose-Resp | 1978 |
Effects of diethylcholine in two animal models of Parkinsonism tremors.
Topics: Animals; Brain Chemistry; Carbachol; Choline; Disease Models, Animal; Male; Mice; Parkinson Disease, | 1979 |
[Parkinson syndrome after administration of acetylcholine into the caudate nuclei].
Topics: Acetylcholine; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Electrodes, Implanted; El | 1989 |
[Modelling of the parkinsonian syndrome by the administration of kainic acid into the caudate nucleus].
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Drug Evaluation, Preclinical; Electrodes, Implante | 1987 |